<DOC>
	<DOCNO>NCT02954653</DOCNO>
	<brief_summary>Two part , dose escalation dose expansion study . Open label , multi center , non randomize , multiple dose , safety , pharmacokinetic pharmacodynamic study single agent PF-06747143 sequential dose level adult patient refractory relapse AML order establish maximum tolerate dose ( MTD ) , recommend Phase 2 dose ( RP2D ) maximally permit dose ( MPD ) follow 3 arm dose expansion PF-06747143 combination standard care chemotherapy adult patient AML .</brief_summary>
	<brief_title>A Study Of PF-06747143 , As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>Patients receive intravenous ( IV ) PF-06747143 weekly infusion ( QW ) 28 day cycle escalate dos . The propose dosing scheme include 0.3 , 1.0 , 3.0 , 10 , 15 , 20 mg/kg . Patients monitor dose limit toxicity ( DLT ) dose escalation order define MTD . Two three arm dose expansion include PF-06747143 combination standard care chemotherapy include safety lead . The third arm , pending clinical data , PF-06747143 single agent .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Part 1 Part 2 cohort 3 : ( AML patient bone marrow ( BM ) peripheral blood ( PB ) blast count 20 % ) : refractory and/or relapse standard therapy available : Patients fail relapse least 2 previous induction regimen ; Patients age 65 year old adverse cytogenetics fail relapse least one prior induction regimen . Part 2 Cohort 1 2 : 1 . Newly diagnose , previously untreated de novo secondary AML population ( AML bone marrow peripheral blast count 20 % ) : Cohort 1 : Fit receive intensive remission induction chemotherapy . Cohort 2 : Unfit receive consider candidate intensive remission induction chemotherapy . Life expectancy least 12 week . Hydroxyurea allow prior Day 1 keep peripheral white blood cell ( WBC ) count less equal 10,000/uL ; must cease 24 hour prior first dose . Age great equal 18 year old . Eastern Cooperative Oncology Group ( ECOG ) performance status : 0 2 . Resolved acute effect prior therapy . Adequate renal hepatic function . Negative serum/urine pregnancy test ( female childbearing potential ) . Patients acute promyelocytic leukemia ( APL ) , AML know central nervous system ( CNS ) involvement unless patient complete treatment CNS disease , recover acute effect therapy prior study entry , neurologically stable . Patient known refractory platelet pack red cell transfusion per institutional guideline . Prior treatment compound target CXCR4 . Chronic systemic corticosteroid treatment . Known suspected hypersensitivity recombinant human protein . Chronic graft versus host disease ( GVHD ) , active GVHD Grade 1 skin involvement , GVHD require immunosuppressive treatment ( Part 1 cohort 3 ) . Not recovered stem cell transplant associate toxicity ( Part 1 cohort 3 ) . Prior treatment hypomethylating agent chemotherapy antecedent myelodysplastic syndrome ( MDS ) ( Part 2 , cohort 2 ) AML associate favorable risk karyotype , include inv ( 16 ) , ( 8 ; 21 ) , ( 16 ; 16 ) , ( 15 ; 17 ) ( cohort 2 ) Candidates allogeneic stem cell transplant ( Part 2 , cohort 2 ) Known hypersensitivity cytarabine daunorubicin ( Part 2 , cohort 1 ) decitabine azacitidine mannitol ( Part 2 , cohort 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
</DOC>